CARA Stock Recent News
CARA LATEST HEADLINES
Merger creates a Nasdaq-listed, clinical-stage biopharmaceutical company – Tvardi Therapeutics – developing novel treatments targeting STAT3 to treat fibrosis-driven diseases.
STAMFORD, Conn., April 14, 2025 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”), today announced that its Board of Directors (the “Board”) has approved a 1-for-3 reverse stock split of its outstanding shares of common stock.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cara Therapeutics, Inc. (NasdaqCM: CARA) and Tvardi Therapeutics, Inc. Pursuant to the terms of the agreement, upon completion of the Merger, Cara shareholders are expected to own approximately 17.0% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are ad.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cara Therapeutics, Inc. (NasdaqCM: CARA) and Tvardi Therapeutics, Inc. Pursuant to the terms of the agreement, upon completion of the Merger, Cara shareholders are expected to own approximately 17.0% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are ad.
Shares of Cara Therapeutics Inc CARA tanked in early trading on Thursday, with the Dow shedding more than 100 points.
Cara Therapeutics (NASDAQ: CARA ) stock is falling hard on Thursday after the development-stage biopharmaceutical company announced new data from a clinical trial. This data comes from the company's Part A KOURAGE-1 study.
Cara Therapeutics said on Wednesday it will discontinue a mid-to-late stage study for a neurological condition that causes itching after its experimental drug did not demonstrate a meaningful clinical benefit compared to placebo.
– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with notalgia paresthetica (NP).
Cara Therapeutics (CARA) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.49 per share a year ago.
STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will report first quarter 2024 financial results on Monday, May 13, 2024, after the U.S. markets close. The press release will be available under “Press Releases” in the Investors section of the Company's website at www.CaraTherapeutics.com.